Date: 2016-02-29
Type of information: Collaboration agreement
Compound: Immunovia’s IMMray™ SLE-d (IMMray™systemic lupus erythematosus biomarker signatures)
Company: Immunovia (Sweden) undisclosed multinational life science company
Therapeutic area: Autoimmune diseases - Diagnostic
Type agreement: collaboration
Action mechanism: diagnostic test/biomarker signature. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis.
Disease: systemic lupus erythematosus (SLE)
Details: * On February 29th, 2016, Immunovia announced that the company has entered into an agreement with a large multinational life science company to run joint studies aimed at expanding the applications area of IMMray™, to autoimmune diseases. The market for systemic lupus erythematosus (SLE) diagnosis is large as it is estimated that 5 million people suffer from SLE worldwide, with 100,000 new cases reported every year. As one of the most difficult to diagnose and monitor autoimmune diseases, SLE is also known as “the great imitator” because its symptoms are similar to other diseases such as rheumatoid arthritis, vasculitis, Sjögrens syndrome, thyroid and, blood disorders. Currently there is no single serological and/or urinary test available to clinicians to diagnose SLE. The two studies are due for completion during 2016. The first is a randomized blind study on the IMMray™ SLE-d platform to further validate Immunovia´s current results. The second study will compare an SLE cohort with patients with similar symptoms, but not autoimmune diseases.
Financial terms:
Latest news:
